Drugs in Dev.
Orthopedics/Orthopedic Surgery
Phase I/ Phase II

Lead Product(s) : Autologous Nucleus Pulposus Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease
Details : Autologous Nucleus Pulposus Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Intervertebral Disc Degeneration.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 11, 2025
Lead Product(s) : Autologous Nucleus Pulposus Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Andecaliximab
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Andecaliximab in Spinal Cord Injury Patients at Risk of Ectopic Bone Growth
Details : Andecaliximab is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Ossification, Heterotopic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 17, 2025
Lead Product(s) : Andecaliximab
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Methylprednisolone
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty
Details : Methylprednisolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthroplasty, Replacement, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Methylprednisolone
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NVDX3
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Safety Trial with NVDX3
Details : NVDX3 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wrist Fractures.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : NVDX3
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rebonuputemcel
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DiscGenics Gets FDA Nod for Phase III Trial of Injectable Disc Progenitor Cells
Details : Rebonuputemcel is an allogeneic, injectable disc progenitor cell therapy, is under investgaten for painful lumbar degenerative disc disease.
Product Name : IDCT
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 16, 2024
Lead Product(s) : Rebonuputemcel
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NVDX3
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe
Deal Size : Inapplicable
Deal Type : Inapplicable
Proof-of-concept Study with NVDX3 for Treatment of Distal Radius Fractures.
Details : NVDX3 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Wrist Fractures.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : NVDX3
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : PrimeVigilance Ltd | Data Investigation Company Europe
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility in patients with CPT.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rebonuputemcel
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : High dose IDCT (Allogeneic Discogenic Progenitor Cell Therapy) also produced clinically meaningful, statistically significant improvements in function and quality of life by 12 weeks following intradiscal injection with durability sustained at the one-ye...
Product Name : IDCT
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : Rebonuputemcel
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AGA111
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
Details : AGA111 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Intervertebral Disc Degeneration.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : AGA111
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
